Traditional and emerging antifungal therapies

Proc Am Thorac Soc. 2010 May;7(3):222-8. doi: 10.1513/pats.200906-048AL.

Abstract

Invasive mycoses continue to be a major problem in the growing population of immunosuppressed patients. More antifungal agents are now available than ever. The options are many, with more efficacies and less toxicity than in the past. These agents differ in terms of spectrum of activity, pharmacologic properties, and indications. In this article we discuss the three major classes of antifungal agents: the polyens, the triazoles, and the echinocandins. The emphasis is placed on their clinical use, side effects, drug interactions, and other practical issues.

Publication types

  • Review

MeSH terms

  • Amphotericin B / administration & dosage
  • Amphotericin B / adverse effects
  • Anidulafungin
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects
  • Antifungal Agents / classification
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use*
  • Caspofungin
  • Drug Therapy, Combination
  • Echinocandins / administration & dosage
  • Echinocandins / pharmacology
  • Fluconazole / therapeutic use
  • Humans
  • Itraconazole / therapeutic use
  • Lipopeptides / administration & dosage
  • Micafungin
  • Pyrimidines / adverse effects
  • Triazoles / adverse effects
  • Triazoles / pharmacokinetics
  • Triazoles / therapeutic use
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Pyrimidines
  • Triazoles
  • Itraconazole
  • posaconazole
  • Amphotericin B
  • Fluconazole
  • Anidulafungin
  • Caspofungin
  • Voriconazole
  • Micafungin